Susceptibility of PTEN-positive metastatic tumors to small interfering RNA targeting the mammalian target of rapamycin

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 1, 2015, Pages 185-194

  Koide, Hiroyuki ^a   Asai, Tomohiro ^a   Kato, Hiroki ^a   Yonenaga, Norihito ^a   Yokota, Masafumi ^a   Ando, Hidenori ^a   Dewa, Takehisa ^b   Nango, Mamoru ^b   Maeda, Noriyuki ^c   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

^c Nippon Fine Chemical Co Ltd   (Japan)

Author keywords

Angiogenesis; Mammalian target of rapamycin; Polycation liposomes; PTEN; Small interfering RNA

Indexed keywords

CYTOLOGY; DERMATOLOGY; ENDOTHELIAL CELLS; LIPOSOMES; MAMMALS; ONCOLOGY; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; RNA; TUMORS;

ANGIOGENESIS; MAMMALIAN TARGET; POLYCATIONS; PTEN; SMALL INTERFERING RNA;

ANTIBIOTICS;

ALANYLPROLYLARGINYLPROLYLGLYCINE DICETYL PHOSPHATE TETRAETHYLENEPENTAMINE BASED POLYCATION LIPOSOME SMALL INTERFERING RNA MAMMALIAN TARGET OF RAPAMYCIN; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYETHYLENE GLYCOL DICETYL PHOSPHATE TETRAETHYLENEPENTAMINE BASED POLYCATION LIPOSOME SMALL INTERFERING RNA GREEN FLUORESCENT PROTEIN; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG; DIOLEOYL PHOSPHATIDYLETHANOLAMINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; ETHYLENEDIAMINE DERIVATIVE; LIPOSOME; MACROGOL DERIVATIVE; MTOR PROTEIN, MOUSE; PHOSPHATIDYLETHANOLAMINE; PTEN PROTEIN, MOUSE; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; TETRAETHYLENEPENTAMINE;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; LIPOSOMAL DELIVERY; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RNA INTERFERENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; EXPERIMENTAL MELANOMA; MALE; MELANOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION;

MAMMALIA; MURINAE; MUS; RODENTIA; TEPA;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; CELL PROLIFERATION; ETHYLENEDIAMINES; LIPOSOMES; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHATIDYLETHANOLAMINES; PHOSPHORYLATION; POLYETHYLENE GLYCOLS; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; TOR SERINE-THREONINE KINASES;

EID: 84919625483     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.09.003     Document Type: Article

References (33)

1. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004, 4(5):335-348.
2. Bjornsti M.A., Houghton P.J. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004, 5(6):519-523.
3. Carayol N., Vakana E., Sassano A., Kaur S., Goussetis D.J., Glaser H., et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A 2010, 107(28):12469-12474.
4. Harris T.E., Lawrence J.C. TOR signaling. Sci STKE 2003, 2003(212):1-17.
5. Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002, 110(2):163-175.
6. Jacinto E., Hall M.N. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003, 4(2):117-126.
7. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14(14):1296-1302.
8. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001, 98(18):10314-10319.
9. Wang M.Y., Lu K.V., Zhu S., Dia E.Q., Vivanco I., Shackleford G.M., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006, 66(16):7864-7869.
10. Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002, 62(21):6141-6145.
11. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508.
12. Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004, 166(2):213-223.
13. Maehama T., Dixon J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 1999, 9(4):125-128.
14. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006, 7(8):606-619.
15. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501.
16. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007, 13(11):3109-3114.
17. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65(16):7052-7058.
18. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430.
19. Koide H., Asai T., Furuya K., Tsuzuku T., Kato H., Dewa T., et al. Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol Pharm Bull 2011, 34(5):602-608.
20. Asai Tomohiro, Matsushita Saori, Kenjo Eriya, Tsuzuku Takuma, Yonenaga Norihito, Koide Hiroyuki, et al. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery. Bioconjug Chem 2010, 22(3):429-435.
21. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 2002, 21(17):2662-2669.
22. Maeda N., Miyazawa S., Shimizu K., Asai T., Yonezawa S., Kitazawa S., et al. Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs. Biol Pharm Bull 2006, 29(9):1936-1940.
23. Asai T., Matsushita S., Kenjo E., Tsuzuku T., Yonenaga N., Koide H., et al. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery. Bioconjug Chem 2011, 22(3):429-435.
24. Lee D.F., Kuo H.P., Chen C.T., Hsu J.M., Chou C.K., Wei Y., et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130(3):440-455.
25. Lee D.F., Hung M.C. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle 2007, 6(24):3011-3014.
26. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 2001, 12(7):363-369.
27. Fang J., Ding M., Yang L., Liu L.Z., Jiang B.H. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal 2007, 19(12):2487-2497.
28. Walter-Yohrling J., Morgenbesser S., Rouleau C., Bagley R., Callahan M., Weber W., et al. Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res 2004, 10(6):2179-2189.
29. Dimmeler S., Zeiher A.M. Akt takes center stage in angiogenesis signaling. Circ Res 2000, 86(1):4-5.
30. Chiang C.T., Way T.D., Lin J.K. Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21(WAF1/CIP1) expression with rapamycin. Mol Cancer Ther 2007, 6(7):2127-2138.
31. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., et al. Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003, 63(1):196-206.
32. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22(2):159-168.
33. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 2008, 105(45):17414-17419.